Type in a keyword and see the report right away. Explore your online world!
If you have already a Newsmeter account:
You can free sign up for Newsmeter:
x
Lundbeck has announced results from an open-label Phase Ib trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist, in people with advanced Parkinson’s disease experiencing motor symptoms sub-optimally controlled despite optimised non-invasive antiparkinsonian medication.
QIAGEN’s new artificial intelligence (AI) capabilities will reportedly help researchers analyse complex biological and genomic data faster while keeping the scientific evidence behind the results visible.
DDW are only a few weeks away from the Drug Discovery Innovators & Investors (DDII) UK Conference that will be held on 4 November 2026 at etc.venues Monument.
